Serina Therapeutics, Inc. (SER) Form 10-Q — Aug 13, 2026
Serina Therapeutics' 10-Q for the quarter ended June 30, 2026 discloses substantial doubt about its ability to continue as a going concern, with management stating its $23.0 million of cash is not expected to fund operations for the twelve months following the filing. The company raised about $31.3 million in net financing proceeds during the first half of 2026, led by a $21.2 million insider PIPE priced at $2.25 per share plus ATM sales, more than doubling shares outstanding to 25.4 million and restoring stockholders' equity to roughly $18.7 million under its NYSE American compliance plan.
Key figures
- Revenue
- 0
- Total Debt
- 3087000
- Cash Position
- 23024000
- Shares Outstanding
- 25400473
- Q2 net loss
- 6356000
- Authorized shares
- 125000000
- Accumulated deficit
- 76754000
- Pipe gross proceeds
- 21200000
- Pipe price per share
- 2.25
- Six month ga expense
- 6000000
- Six month rnd expense
- 7000000
- Six month operating loss
- 13100000
- Convertible note capacity
- 20000000
- Total stockholders equity
- 18700000
- Atm gross proceeds to date
- 13200000
- Bailey beneficial ownership
- 41%
- Six month financing proceeds
- 31259000
- Six month operating cash used
- 11252000
- Q2 net loss attributable common
- 8932000
- Juvenescence beneficial ownership
- 17%
- Redeemable warrant exercise price
- 5
- Convertible note first tranche drawn
- 5000000
- Six month net loss attributable common
- 15867000
Price after filing
Close on the filing date to close N calendar days later (from $2.85). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.